NasdaqGS:ZVRAPharmaceuticals
Does Zevra Therapeutics Near $8 Reflect Its 92% DCF Upside Potential in 2025?
Wondering if Zevra Therapeutics at around $8 a share is a hidden bargain or just another biotech rollercoaster? You are not alone. Let us break down what the current price might really be telling us.
The stock is roughly flat over the last year, down 1.8%, but that sits on top of a wild 84.7% gain over three years and a 55.5% drop over five years. This pattern hints at shifting market confidence rather than a simple growth story.
Recent attention has centered on Zevra's progress with its...